Traffic Stats
- PR: 0
Adult Site: no
IP: 165.193.247.25
Online
JKureczka: Moving sequencing
into the clinic takes more than just big data http://t.co/kdnqnbDe #biotech
#personalizedmedicine
furqanaisha: RT @NextBio: New
on our blog: Moving sequencing into the clinic takes more than just
big data http://t.co/Gi1tb4gH
NextBio: New on our blog: Moving
sequencing into the clinic takes more than just big data http://t.co/Gi1tb4gH
AntoanetaVlad: RT @NextBio blog:
What can you find out about a drug's effects from existing public
data? Find out in our new tutorial! http://t.co/r019n8L0
NextBio: RT @trished âWhat can you
find out about a drug's effects from existing public data? http://t.co/TA7GqsfRâ based on #BMJ
paper
Company

- Company Name: NextBio
- Homepage: http://www.nextbio.com
- Category: software
- Number of Employees: 75
- Founded: 1-Nov-2004
- Description: Life science Informatics
- Overview:
-
NextBio is privately owned software company that provides a platform for life science researchers to search, discover, and share knowledge across public and proprietary data.
Nextbio was co-founded by Saeid Akhtari, Ilya Kupershmidt and Mostafa Ronaghi in 2004 and based in Cupertino California, USA.
The NextBio Platform is an ontology-based semantic framework that connects highly heterogeneous data and textual information. The semantic framework is based on gene, tissue, disease and compound ontologies. This framework contains information from diverse organisms, platforms, data types and research areas is integrated into and correlated within a single searchable environment using proprietary algorithms. It provides a unified interface for researchers to formulate and test new hypotheses across vast collections of experimental data.
The enterprise version of the NextBio platform is being used in life science R&D and drug development by researchers and clinicians at: Merck Pharmaceutical, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Celgene, Genzyme, Eli Lilly and Company, and [[Regeneron Pharmaceuticals. This enterprise version allows internal, proprietary data to be uploaded and integrated into the NextBio database of publicly-available data. Scientists are using NextBio to improve their ability to identify relevant prognostic and predictive molecular signatures which are significant in their research.
NextBio was a receiver of the Frost & Sullivan North American Life Sciences Customer Value Enhancement Award in 2008. Since the release it has had more than 1,500,000 visitors.
| Name | Title |
| Mohsen Moazami | Investor |
| Satnam Alag | VP of Engineering |
| Name | Title |
| Ilya Kupershmidt | VP of Product Management |
| Saeid Akhtari | President & CEO |







